These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25583815)

  • 21. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olaparib for the treatment of breast cancer.
    Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
    Kim G; Ison G; McKee AE; Zhang H; Tang S; Gwise T; Sridhara R; Lee E; Tzou A; Philip R; Chiu HJ; Ricks TK; Palmby T; Russell AM; Ladouceur G; Pfuma E; Li H; Zhao L; Liu Q; Venugopal R; Ibrahim A; Pazdur R
    Clin Cancer Res; 2015 Oct; 21(19):4257-61. PubMed ID: 26187614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olaparib: first global approval.
    Deeks ED
    Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
    Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olaparib for the treatment of breast cancer.
    Griguolo G; Dieci MV; Guarneri V; Conte P
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    Floquet A; Stoeckle E; Croce S; Longy M; Mc Grogan G; Barouk E; Bubien V; Garbay D; Joly E; Guyon F
    Bull Cancer; 2014 Feb; 101(2):167-74. PubMed ID: 24555961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
    Copur MS; Gauchan D; Brussow K; Clark D; Ramaekers R
    J Clin Oncol; 2015 Aug; 33(23):2582. PubMed ID: 26124479
    [No Abstract]   [Full Text] [Related]  

  • 30. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
    Gartner EM; Burger AM; Lorusso PM
    Cancer J; 2010; 16(2):83-90. PubMed ID: 20404603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olaparib shows promise in multiple tumor types.
    Cancer Discov; 2013 Jul; 3(7):OF5. PubMed ID: 23847380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
    Moore KN; Birrer MJ
    Oncologist; 2018 Jun; 23(6):697-703. PubMed ID: 29593098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olaparib.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2016 Jan; 81(1):171-3. PubMed ID: 26344419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract]   [Full Text] [Related]  

  • 36. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
    PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP inhibitors: targeting the right patients.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.